Out-of-Pocket Cost of Naloxone May Keep Many Uninsured from Using Lifesaving Treatment

The cost of buying the opioid antidote naloxone is out of reach for many uninsured Americans, a hurdle that may keep the treatment from saving more people who overdose on opioids, according to a new RAND Corporation study .read more…
Read More

About The Author

Jonathan Jeriah

See author's posts